Connect Biopharma (NASDAQ:CNTB – Get Free Report) and Janone (NASDAQ:ALTS – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, risk, institutional ownership, profitability and valuation.
Volatility and Risk
Connect Biopharma has a beta of -0.44, indicating that its stock price is 144% less volatile than the S&P 500. Comparatively, Janone has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500.
Institutional and Insider Ownership
58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 6.3% of Janone shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by company insiders. Comparatively, 4.9% of Janone shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
Net Margins | Return on Equity | Return on Assets | |
Connect Biopharma | N/A | N/A | N/A |
Janone | N/A | -2,940.01% | -39.81% |
Analyst Recommendations
This is a breakdown of current ratings and price targets for Connect Biopharma and Janone, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Connect Biopharma | 0 | 0 | 1 | 0 | 3.00 |
Janone | 0 | 0 | 0 | 0 | 0.00 |
Connect Biopharma presently has a consensus target price of $8.00, indicating a potential upside of 614.29%. Given Connect Biopharma’s stronger consensus rating and higher possible upside, analysts plainly believe Connect Biopharma is more favorable than Janone.
Valuation & Earnings
This table compares Connect Biopharma and Janone”s gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Connect Biopharma | $24.12 million | 2.57 | -$59.50 million | N/A | N/A |
Janone | $7.11 million | 13.46 | -$7.81 million | N/A | N/A |
Janone has lower revenue, but higher earnings than Connect Biopharma.
Summary
Connect Biopharma beats Janone on 8 of the 11 factors compared between the two stocks.
About Connect Biopharma
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.
About Janone
JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through three segments: Biotechnology, Recycling, and Technology. The company’s lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs; and designs, develops, and sells cellular transceiver modules and associated wireless services. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.